Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Front Pharmacol ; 11: 324, 2020.
Article in English | MEDLINE | ID: mdl-32390825

ABSTRACT

Pharmacogenetic analysis has generated translational data that could be applied to guide treatments according to individual genetic variations. However, pharmacogenetic counseling in some mestizo (admixed) populations may require tailoring to different patterns of admixture. The identification and clustering of individuals with related admixture patterns in such populations could help to refine the practice of pharmacogenetic counseling. This study identifies related groups in a highly admixed population-based sample from Mexico, and analyzes the differential distribution of actionable pharmacogenetic variants. A subsample of 1728 individuals from the Mexican Genomic Database for Addiction Research (MxGDAR/Encodat) was analyzed. Genotyping was performed with the commercial PsychArray BeadChip, genome-wide ancestry was estimated using EIGENSOFT, and model-based clustering was applied to defined admixture groups. Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP). Allele frequencies were compared with chi-square tests and differentiation was estimated by FST. Seven admixture groups were identified in Mexico. Some, like Group 1, Group 4, and Group 5, were found exclusively in certain geographic areas. More than 90% of the individuals, in some groups (Group 1, Group 4 and Group 5) were found in the Central-East and Southeast region of the country. MTRR p.I49M, ABCG2 p.Q141K, CHRNA5 p.D398N, SLCO2B1 rs2851069 show a low degree of differentiation between admixture groups. ANKK1 p.G318R and p.H90R, had the lowest allele frequency of Group 1. The reduction in these alleles reduces the risk of toxicity from anticancer and antihypercholesterolemic drugs. Our analysis identified different admixture patterns and described how they could be used to refine the practice of pharmacogenetic counseling for this admixed population.

2.
Salud ment ; 40(3): 111-118, May.-Jun. 2017. tab, graf
Article in English | LILACS | ID: biblio-903720

ABSTRACT

Abstract Background Anti-inflammatory, analgesic, anticonvulsant, and other effects have been attributed to cannabis, and so it has been widely used to treat several diseases. Objective To assess the use and therapeutic effects of cannabinoid drugs and the cannabis plant in several diseases. Method We carried out a narrative review of the literature that has reported the use of the cannabis plant (marijuana) and cannabinoid drugs (nabilone, cannabinol and dronabinol, among others). We conducted a search in Medline, Cochrane, SciELO and other web sites. Clinical, controlled, double-blind and randomized studies were included. The route of administration and the cannabinoid drugs used were assessed too. Results Thirty-four studies were included. Nabilone was the cannabinoid drug more commonly used (12 studies), followed by delta-9-tetrahydrocannabinol (THC) (11 studies). It was also found that the marijuana plant and cannabinoid drugs were used to treat many symptoms or diseases. Two studies were reported for Gilles de la Tourette's syndrome. Discussion and conclusion Many scientific studies on the marijuana plant and cannabinoid drugs conclude that these are not as effective as conventional medications and thus their benefits should be taken with caution.


Resumen Antecedentes A la planta de cannabis y a los fármacos cannabinoides se les han atribuido efectos antiinflamatorios, analgésicos y anticonvulsivantes, entre otros, y por ello se han utilizado para tratar diversas patologías. Objetivo Evaluar el uso y los efectos terapéuticos de la planta de cannabis y los fármacos cannabinoides en diversas enfermedades. Método Se utilizó un diseño descriptivo mediante la revisión narrativa de la literatura sobre el uso de la planta de cannabis (mariguana) y los fármacos cannabinoides (nabilona, cannabinol y dronabinol, entre otros) en los buscadores Medline, Cochrane, SciELO y otros. Se incluyeron sólo los estudios clínicos, controlados, doble ciego y aleatorizados, así como la vía de administración y el fármaco cannabinoide utilizado. Resultados Treinta y cuatro estudios cumplieron con los criterios de inclusión. La nabilona fue el fármaco más empleado (12 estudios), seguida del delta-9-tetrahidrocannabinol (THC) (11 estudios). Tanto la planta como los fármacos cannabinoides se utilizaron para tratar diversos síntomas o enfermedades. Dos estudios reportaron su uso para el síndrome de Gilles de la Tourette. Discusión y conclusión La mayoría de los estudios revisados indican que la efectividad de la planta de mariguana o de los fármacos cannabinoides no es superior a la de los fármacos convencionales y que sus beneficios deben tomarse con cautela.

3.
Psicol. conduct ; 24(2): 341-360, mayo-ago. 2016. tab
Article in Spanish | IBECS | ID: ibc-155594

ABSTRACT

El objetivo de este trabajo fue evaluar el cambio de conducta de los padres y de la conducta infantil a partir de su participación en un programa de prácticas de crianza. 128 padres de ocho instituciones de salud pública en México fueron evaluados con autoinformes sobre su conducta y la de sus hijos, y se usó un sistema de observación directa para valorar la utilización de las prácticas de crianza y el comportamiento de los padres. Se utilizó un diseño factorial de 2 (evaluación antes y después) por 2 (por grupo con utilización baja y media). Se encontró que las conductas de los padres que cambian en función de una mayor utilización de los procedimientos generales de prácticas de crianza son el elogio, la interacción social y el seguimiento de instrucciones y el informe de menor uso de castigo, mayor uso de la técnica de ignorar, solucionar problemas, establecer reglas e interacción social-académica. Estudios adicionales deberán confirmar el proceso de adopción comprometido con los procedimientos de crianza positiva en la reducción del comportamiento problemático infantil


The goal of the study was to assess parents and children behavior on the basis of their participation in a raising practices program. 128 parents from 8 public health institutions in Mexico were assessed with self-reports about their behaviors and their children’s, and a direct observational system was used to determine the use of raising practices and parents behaviors. A factorial design of two (before and after assessment) by two (low and middle use) was used. The results suggest that the parental behaviors that change in function of higher use of the child raising practices are praising, social interaction and following instructions; and the report of lower use of punishment, more use of the ignoring technique, problem solving, establishment of rules and academic social interaction. Additional studies should confirm the engaged adoption process associated with child raising practices and the reduction of problematic behavior in children


Subject(s)
Humans , Child Rearing , Parenting , Child Behavior/psychology , Child Behavior Disorders/psychology , Evaluation of the Efficacy-Effectiveness of Interventions , Parents/education , Child Care/statistics & numerical data , Parent-Child Relations
SELECTION OF CITATIONS
SEARCH DETAIL
...